Kafadar İhsan, Kılıç Betül Aydın, Arapoglu Mujde, Yalçın Koray, Dalgıç Nazan
Department of Pediatrics, Division of Pediatric Neurology, Sisli Etfal Training & Research Hospital, Istanbul, Turkey.
Department of Pediatrics, Sisli Etfal Training & Research Hospital, Istanbul, Turkey.
J Child Neurol. 2015 Jan;30(1):63-8. doi: 10.1177/0883073814529822. Epub 2014 Apr 15.
The aim of this study was to determine the alterations in thyroid function during carbamazepine or valproate monotherapy in a prospective study. Forty patients treated with valproate, 33 patients treated with carbamazepine, and 36 control patients, all aged between 2 and 18 years, were enrolled in our study. Serum levels of thyroid hormones were measured before the beginning of the antiepileptic therapy and at 6 and 12 months of treatment. Carbamazepine-treated patients showed mean serum thyroid hormone levels significantly lower than baseline evaluation and the control group. Thyroid-stimulating hormone levels at 6 and 12 months were not significantly different in carbamazepine treated patients. Serum hormone levels did not change during valproate treatment. Thyroid-stimulating hormone levels were significantly higher at the 12th month of valproate treatment. Our data suggest that although carbamazepine causes significant alterations in thyroid hormone levels, these changes do not lead to clinical symptoms at the follow-up period of 12 months.
本前瞻性研究的目的是确定卡马西平或丙戊酸单药治疗期间甲状腺功能的变化。本研究纳入了40例接受丙戊酸治疗的患者、33例接受卡马西平治疗的患者以及36例对照患者，所有患者年龄均在2至18岁之间。在抗癫痫治疗开始前以及治疗6个月和12个月时测量血清甲状腺激素水平。接受卡马西平治疗的患者血清甲状腺激素平均水平显著低于基线评估值和对照组。接受卡马西平治疗的患者在6个月和12个月时促甲状腺激素水平无显著差异。丙戊酸治疗期间血清激素水平未发生变化。丙戊酸治疗第12个月时促甲状腺激素水平显著升高。我们的数据表明，虽然卡马西平会引起甲状腺激素水平的显著变化，但在12个月的随访期内这些变化并未导致临床症状。
